10.1007/s13312-022-2594-2 57 TillemansM
Lonn M, Svedberg P, Nygren J, Jarbin H, Aili K, Larsson I
Fun fact from a data deep dive that I helped work on: Medicaid spending on GLP-1s has grown exponentially over the past five years with 36 states now covering at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda) Why
I just remember everyone telling me GLP-1s, or taking the Ozempic or the Mounjaro, Listen, its gonna hurt your stomach a little bit, he said
GliSODin is a new approach to antioxidant supplementation, entirely different from supplementing with conventional dietary antioxidants
(2016b) revealed that Tanshinone IIA mitigated the overactivity of glycogen synthase kinase (GSK)3, as well as the hyperactivation of its downstream mitogen-activated protein kinases, which are fundamentally involved in renal fibrogenesis and inflammatory processes